{"id":194703,"date":"2025-06-18T15:18:13","date_gmt":"2025-06-18T15:18:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/194703\/"},"modified":"2025-06-18T15:18:13","modified_gmt":"2025-06-18T15:18:13","slug":"eli-lillys-genetic-medicine-bet-on-verve-therapeutics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/194703\/","title":{"rendered":"Eli Lilly\u2019s Genetic Medicine Bet On Verve Therapeutics"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/06\/1750259893_203_960x0.jpg\" alt=\"Verve Therapeutics Doses First Patient With CRISPR\" data-height=\"1452\" data-width=\"2178\" style=\"position:absolute;top:0\"\/><\/p>\n<p class=\"color-body light-text\" role=\"button\">Cambridge, MA &#8211; July 11: Verve CEO and cofounder Sekar Kathiresan. Cambridge company Verve &#8230; More Therapeutics announced on Tuesday morning that it has dosed the first patient with its new CRISPR gene editing technology called base editing, which changes a single letter of DNA into another letter to treat genetic disease. (Photo by Suzanne Kreiter\/The Boston Globe via Getty Images)<\/p>\n<p>Boston Globe via Getty Images<\/p>\n<p><a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/LLY\/\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/\" aria-label=\"Eli Lilly\u2019s\">Eli Lilly\u2019s<\/a> $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine. The pharmaceutical behemoth paid a substantial premium of approximately 113% above Verve\u2019s 30-day volume-weighted average trading price, triggering an 80% surge in Verve\u2019s stock price on June 17, 2025.<\/p>\n<p>The acquisition aligns with Eli Lilly\u2019s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve\u2019s innovative gene-editing technology, which permanently deactivates the PCSK9 gene to address high cholesterol, represents a breakthrough approach to cardiovascular disease treatment. This move positions Lilly to capture value in the high-impact cardiovascular therapeutics market while expanding its genetic medicine capabilities. On a separate note, see \u2013 <a class=\"_1-FLFW4R\" href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2025\/06\/17\/soundhound-ai-buy-sell-or-hold-soun-stock-at-10\/\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/sites\/greatspeculations\/2025\/06\/17\/soundhound-ai-buy-sell-or-hold-soun-stock-at-10\/\" target=\"_self\" aria-label=\"SoundHound AI: Buy, Sell Or Hold SOUN Stock At $10?\" rel=\"noopener\">SoundHound AI: Buy, Sell Or Hold SOUN Stock At $10?<\/a><\/p>\n<p>Despite the premium paid for Verve, Eli Lilly\u2019s core valuation metrics suggest reasonable positioning relative to historical norms. Trading at <strong>57 times<\/strong> trailing adjusted earnings of $13.76 per share, the company\u2019s current valuation sits below its three-year average P\/E ratio of 66 times. This suggests that while the stock commands a premium, it remains within established valuation parameters given the company\u2019s strong financial and operational performance as seen in <a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/LKPMNhKB\/Buy-Or-Fear-Eli-Lilly-LLY-Stock-\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/LKPMNhKB\/Buy-Or-Fear-Eli-Lilly-LLY-Stock-\" aria-label=\"Buy or Sell Eli Lilly Stock\"><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/LKPMNhKB\/Buy-Or-Fear-Eli-Lilly-LLY-Stock-\">Buy or Sell Eli Lilly Stock<\/strong><\/a> dashboard.<\/p>\n<p>Several key risks warrant attention in evaluating Eli Lilly stock:<\/p>\n<ul>\n<li><a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/QUFaLtoo\/How-Low-Can-Eli-Lilly-Stock-Go-In-A-Market-Crash-\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/QUFaLtoo\/How-Low-Can-Eli-Lilly-Stock-Go-In-A-Market-Crash-\" aria-label=\"Eli Lilly\u2019s Market Volatility Risk:\"><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/QUFaLtoo\/How-Low-Can-Eli-Lilly-Stock-Go-In-A-Market-Crash-\">Eli Lilly\u2019s Market Volatility Risk:<\/strong><\/a> Historical data demonstrates Eli Lilly\u2019s vulnerability during broader market downturns, including underperformance during the 2022 inflation crisis. This pattern suggests potential sensitivity to macroeconomic shocks.<\/li>\n<li><a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/HeLuxt9E\/Eli-Lilly-LLY-Valuation-Ratios-Comparison\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/HeLuxt9E\/Eli-Lilly-LLY-Valuation-Ratios-Comparison\" aria-label=\"LLY Valuation Sensitivity:\"><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/LLY\/no-login-required\/HeLuxt9E\/Eli-Lilly-LLY-Valuation-Ratios-Comparison\">LLY Valuation Sensitivity:<\/strong><\/a> The company\u2019s elevated multiple, while justified by growth prospects, creates vulnerability to any disappointment in execution or market sentiment shifts.<\/li>\n<li><strong>Portfolio Concentration:<\/strong> Heavy reliance on obesity drug demand creates exposure to regulatory changes or competitive pressures in this therapeutic area.<\/li>\n<\/ul>\n<p>The Verve Therapeutics acquisition reinforces Eli Lilly\u2019s position as an attractive investment opportunity, supported by strong demand for its obesity treatments and successful diversification into high-potential therapeutic areas. That said, there always remains a meaningful risk when investing in a single, or just a handful, of stocks. Consider Trefis<a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/RsQ6oXgC\/High-Quality-Portfolio?from=Forbes&amp;source=LLY-2025-06-18&amp;CTA=LinkBlock\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/RsQ6oXgC\/High-Quality-Portfolio?from=Forbes&amp;source=LLY-2025-06-18&amp;CTA=LinkBlock\" aria-label=\"High Quality (HQ) Portfolio\"> High Quality (HQ) Portfolio<\/a> which, with a collection of 30 stocks, has a track record of <strong>comfortably outperforming the S&amp;P 500<\/strong> over the last 4-year period. <strong>Why is that?<\/strong> As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in <a class=\"color-link\" href=\"https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/37ZjifdJ\/High-Quality-Portfolio-Fact-Sheet?Forbes&amp;source=LLY-2025-06-18CTA=LinkBlock\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/37ZjifdJ\/High-Quality-Portfolio-Fact-Sheet?Forbes&amp;source=LLY-2025-06-18CTA=LinkBlock\" aria-label=\"HQ Portfolio performance metrics\">HQ Portfolio performance metrics<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Cambridge, MA &#8211; July 11: Verve CEO and cofounder Sekar Kathiresan. Cambridge company Verve &#8230; More Therapeutics announced&hellip;\n","protected":false},"author":2,"featured_media":194704,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[79362,267,79365,79367,79368,79366,5489,14413,70,16,15,79361,79363,79364],"class_list":{"0":"post-194703","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-eli-lilly-stock","9":"tag-genetics","10":"tag-lly-revenue","11":"tag-lly-risks","12":"tag-lly-stock","13":"tag-lly-valuation","14":"tag-pharmaceuticals","15":"tag-sp-500","16":"tag-science","17":"tag-uk","18":"tag-united-kingdom","19":"tag-verv-stock","20":"tag-verve-stock","21":"tag-verve-therapeutics"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114705039593334411","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/194703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=194703"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/194703\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/194704"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=194703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=194703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=194703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}